Collegium Pharmaceutical (COLL) Change in Acquisitions & Divestments (2023 - 2026)

Collegium Pharmaceutical's Change in Acquisitions & Divestments history runs 4 years deep, the most recent figure standing at $20.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 17.63% year-over-year to $20.0 million in Q1 2026; TTM through Mar 2026 was $68.2 million, a 22.58% decrease from a year earlier, with the FY2025 full-year figure at $65.2 million, down 29.62% from the prior year.
• Change in Acquisitions & Divestments climbed to $20.0 million in Q1 2026 per COLL's latest filing, from $19.8 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $29.4 million in Q3 2024 and bottomed at $13.8 million in Q2 2025.
• The 4-year median for Change in Acquisitions & Divestments is $18.4 million (2025), against an average of $19.4 million.
• Biggest YoY gain for Change in Acquisitions & Divestments was 24.2% in 2025; the steepest drop was 50.49% in 2025.
• Year by year, Change in Acquisitions & Divestments stood at $16.0 million in 2023, then fell by 0.15% to $16.0 million in 2024, then increased by 24.2% to $19.8 million in 2025, then grew by 0.83% to $20.0 million in 2026.
• Per Business Quant, the three latest COLL Change in Acquisitions & Divestments figures stand at $20.0 million (Q1 2026), $19.8 million (Q4 2025), and $14.6 million (Q3 2025).